Beta Bionics (NASDAQ:BBNX) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage issued a neutral rating and a $20.00 price target on the stock.

Separately, Robert W. Baird assumed coverage on Beta Bionics in a research note on Thursday. They set a “neutral” rating and a $20.00 target price on the stock.

Beta Bionics Trading Down 4.3 %

NASDAQ BBNX opened at $20.87 on Thursday. Beta Bionics has a 12-month low of $20.84 and a 12-month high of $24.50.

Insider Buying and Selling

In other news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $17.00 per share, for a total transaction of $17,000,000.00. Following the purchase, the insider now owns 3,901,599 shares in the company, valued at $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mike Mensinger acquired 33,350 shares of Beta Bionics stock in a transaction dated Friday, January 31st. The stock was purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now owns 59,019 shares of the company’s stock, valued at approximately $1,003,323. The trade was a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.